V. Panday

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

J. Schellens, J. Beijnen, J. Schellens, 1999, British Journal of Cancer.

Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel

J. Beijnen, J. Vermorken, M. Huizing, 1997 .

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

J. Schellens, H. Rosing, J. Beijnen, 1999, Pharmacological research.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

J. Schellens, H. Rosing, J. Beijnen, 1998, Anti-cancer drugs.

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

J. Beijnen, W. W. ten Bokkel Huinink, J. Vermorken, 1997, Seminars in oncology.

Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel

J. Beijnen, O. van Tellingen, P. Willemse, 1999 .

Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

G. Giaccone, J. Schellens, J. Beijnen, 1998, Clinical drug investigation.

Urinary excretion of paclitaxel and metabolites in a large series study

H. Rosing, J. Beijnen, L. V. van Warmerdam, 1998 .